The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease

被引:30
|
作者
Pilotto, A
Franceschi, M
Di Mario, F
Leandro, G
Bozzola, L
Valerio, G
机构
[1] San Bortolo Hosp, Dept Geriatr, Vicenza, Italy
[2] Univ Padua, Dept Gastroenterol, I-35100 Padua, Italy
[3] Dept Gastroenterol, Castellana Grotte, Italy
[4] Clin Pathol Unit, Vicenza, Italy
关键词
Helicobacter pylori; peptic ulcer; endoscopy;
D O I
10.1159/000022000
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The objective of this study was to evaluate the long-term efficacy of Helicobacter pylori (HP) eradication treatment in elderly patients with HP-associated peptic ulcer. A total of 56 subjects, 25 affected with gastric ulcer (GU, 9 males, 16 females, mean age 77.8 years, range 67-93) and 31 with duodenal ulcer (DU, 19 males, 12 females, mean age 76.5 years, range 65-87) were confirmed to be HP-positive by gastric histology and the rapid urease test. All patients were then consecutively treated with omeprazole for 4 weeks plus one or two antibiotics for 1 week as anti-HP treatment. Clinical checkups were then performed every 3 months for 1 year for the evaluation of symptoms and clinical recurrences. Endoscopy with gastric biopsies was repeated after 1, 3 and 12 months for the evaluation of ulcer healing, HP infection and chronic gastritis activity. Statistical analysis was performed by means of the Student t test for unpaired data, the Fisher exact test (two-tailed), and the McNemar chi(2) test. After 4 weeks of treatment, endoscopy confirmed healing of the ulcer in all patients, regardless of the treatment used to cure HP infection. Two months after the end of therapy, a total of 44 patients were HP-negative and 12 patients were still HP-positive. During the 1-year follow-up period 1/44 (2.2%) of the HP-eradicated patients and 5/12 (41.6%) of the still HP-positive patients suffered relapses (p = 0.001): the difference between the two groups remained statistically significant when patients were divided into the subgroups, GU (p = 0.01) and DU (p = 0.04). Two months after the end of therapy, there was still a significant reduction of symptoms both in HP-eradicated (p < 0.0000) and in HP-positive (p = 0.002) patients. After 1 year, however, there was a significantly decreased symptomatology only in HP-eradicated subjects (p < 0.0000) and not in patients still HP-positive. After both 2 months and 1 year of follow-up, chronic gastritis activity demonstrated a significant improvement only in HP-eradicated patients (p = 0.0000). In conclusion, the eradication of HP infection significantly improved the long-term clinical outcome of peptic ulcer disease in the elderly, reducing the recurrences of GU and DU, the patient's symptomatology and the histological signs of chronic gastritis activity. The cure of HP infection is, therefore, strongly recommended in elderly patients with HP-associated peptic ulcer disease.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 50 条
  • [41] Peptic ulcer disease in south Ethiopia is strongly associated with Helicobacter pylori
    Henriksen, TH
    Nysæter, G
    Madebo, T
    Setegn, D
    Brorson, O
    Kebede, T
    Berstad, A
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (02) : 171 - 173
  • [42] HELICOBACTER PYLORI AND PEPTIC ULCER IN CIRRHOTIC PATIENTS
    Rahimkhani, Monireh
    Ghofrani, Hadi
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2008, 24 (06) : 849 - 852
  • [43] Audit of the change of outcome of peptic ulcer disease following treatment of Helicobacter pylori
    Jost, C
    Marbet, UA
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 128 (03) : 64 - 71
  • [44] One-day combined therapy of children with Helicobacter pylori-associated peptic disease
    Artan, R
    Gelen, T
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (04) : 798 - 798
  • [45] Helicobacter pylori-associated antibodies in patients with duodenal ulcer, gastric and oesophageal adenocarcinoma
    Grimley, CE
    Holder, RL
    Loft, DE
    Morris, A
    Nwokolo, CU
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (05) : 503 - 509
  • [46] The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori-associated gastric and duodenal peptic ulcer disease
    Veliev, A. M.
    Maev, I., V
    Andreev, D. N.
    Dicheva, D. T.
    Zaborovskii, A., V
    Lobanova, E. G.
    Bektemirova, L. G.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (08) : 28 - 33
  • [47] Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients
    Ford, A. C.
    Delaney, B. C.
    Forman, D.
    Moayyedi, P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [48] LONG-TERM RISK OF PEPTIC-ULCER DISEASE IN PEOPLE WITH HELICOBACTER-PYLORI INFECTION - A COMMUNITY-BASED STUDY
    CULLEN, DJE
    COLLINS, BJ
    CHRISTIANSEN, KJ
    EPIS, J
    WARREN, JR
    CULLEN, KJ
    GASTROENTEROLOGY, 1993, 104 (04) : A60 - A60
  • [49] HELICOBACTER-PYLORI AND PEPTIC-ULCER DISEASE
    FELDMAN, M
    PETERSON, WL
    WESTERN JOURNAL OF MEDICINE, 1993, 159 (05): : 555 - 559
  • [50] HELICOBACTER-PYLORI AND PEPTIC-ULCER DISEASE
    BAGSHAW, PF
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (07): : 518 - 520